{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-076880","form_type":"8-K","ticker":"SILO","cik":"0001514183","company_name":"Silo Pharma, Inc.","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.934211+00:00","generated_at":"2026-06-21T10:50:21.858540+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Silo Pharma provides pipeline update, cites $12M cash and zero debt","bullets":["Cash over $12M, no debt, listed on Nasdaq; pursuing 505(b)(2) pathway for several assets.","SP-26 (ketamine for fibromyalgia) preparing pre-IND submission; safety evaluation underway.","SPU-16 (MS) and SPU-21 (RA) under license from University of Maryland; SPU-21 inhibited arthritis in preclinical model.","SPC-14 (Alzheimer's) showed proof-of-concept in mouse model; SPC-15 (PTSD) under Columbia option.","Sponsored clinical study with UCSF on psilocybin's anti-inflammatory effects."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-076880","json":"https://secwatch.observer/filing/0001213900-22-076880.json","markdown":"https://secwatch.observer/filing/0001213900-22-076880.md","text":"https://secwatch.observer/filing/0001213900-22-076880.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022076880/0001213900-22-076880-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1514183/000121390022076880/ea169527-8k_silopharma.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T10:50:21.858540+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}